Balanced news tone
News Sentiment
NMRA sentiment intelligence
Neumora Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
51
Balanced news tone
59 relevant articles
News tone and price action are not far from neutral.
81/100 classification confidence.
directly relevant articles
high-authority source matches
+0.6% over one week, -5.6% over four weeks, trend inactive, and below fair value.
Neumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA)
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
81/100 classification
One-week reaction
0.6%
Price digesting
Trend fit
Trend inactive
-5.6% over four weeks
Fair value
-75.2%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
17
Neutral
27
Negative
15
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
MarketBeat
Direct company coverage
Neumora Therapeutics Target of Unusually Large Options Trading (NASDAQ:NMRA)
Neumora Therapeutics (NASDAQ:NMRA) experienced unusually heavy options trading on Thursday, with investors purchasing 12,405 put options, a 1,007% increase over its daily average. The stock's price fell by 1.0% to $1.61, and the company, a small-cap biotech with a market value of
- Tone
- Negative 39/100
- Event
- Analyst action
- Published
- 16 Jul 2026 16:42
- Source
- MarketBeat
Moomoo
Direct company coverage
Neumora Therapeutics Is Maintained at Outperform by RBC Capital
RBC Capital has reiterated its Outperform rating on Neumora Therapeutics. This indicates a continued positive outlook on the company's stock performance.
- Tone
- Positive 69/100
- Event
- Analyst action
- Published
- 14 Jul 2026 08:14
- Source
- Moomoo
MarketBeat
Direct company coverage
Neumora Therapeutics (NASDAQ:NMRA) Price Target Cut to $5.00 by Analysts at Royal Bank Of Canada
Royal Bank of Canada has reduced its price target for Neumora Therapeutics (NASDAQ:NMRA) from $7.00 to $5.00, while maintaining an "outperform" rating. This new target implies a significant upside, despite other analysts like HC Wainwright, Needham, and Mizuho also cutting their
- Tone
- Negative 35/100
- Event
- Analyst action
- Published
- 13 Jul 2026 14:10
- Source
- MarketBeat
marketscreener.com
Direct company coverage
RBC Cuts Price Target on Neumora Therapeutics to $5 From $7, Keeps Outperform, Speculative Risk
RBC Capital Markets has reduced its price target for Neumora Therapeutics (NMRA) from $7 to $5, while maintaining an "Outperform" rating with a "Speculative Risk" assessment. This adjustment comes despite the company's recent inclusion in several Russell indexes, including the Ru
- Tone
- Negative 40/100
- Event
- Analyst action
- Published
- 13 Jul 2026 11:10
- Source
- marketscreener.com
The Globe and Mail
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 03:32
- Source
- The Globe and Mail
Market source
Direct company coverage
Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation
Neumora Therapeutics (NMRA) has seen its fair value estimate cut by analysts from US$8.91 to US$6.53 per share, a 27% reduction, following the discontinuation of its drug navacaprant. Despite the setback, some analysts remain positive about the company's remaining pipeline, while
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 11 Jul 2026 09:08
- Source
- Market source
Moomoo
Direct company coverage
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $5 to $7
This article provides a quick look at analyst ratings for Neumora Therapeutics (NMRA.US), indicating a forecast share price between $5 and $7. The ratings reflect current market sentiment and expert opinions on the company's financial outlook and stock performance. Investors can
- Tone
- Positive 59/100
- Event
- Guidance
- Published
- 09 Jul 2026 20:10
- Source
- Moomoo
Market source
Direct company coverage
Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 07 Jul 2026 05:53
- Source
- Market source
Insider Monkey
Direct company coverage
5 Best Get Rich Quick Stocks to Buy Right Now
This article identifies Neumora Therapeutics, Inc. (NASDAQ:NMRA) as a "get rich quick" stock with significant upside potential, despite recent price target cuts following negative Phase 3 study outcomes. Analysts express optimism for its "highly intriguing" pipeline, which includ
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 06 Jul 2026 13:14
- Source
- Insider Monkey
marketscreener.com
Direct company coverage
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000 Growth Benchmark
Neumora Therapeutics, Inc. (NasdaqGS: NMRA) has been added to the Russell 3000 Growth Benchmark, as well as several other Russell indices including the Russell 2000 Index and Russell Microcap Growth Benchmark. This inclusion highlights Neumora's presence in the market as a clinic
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 01 Jul 2026 08:14
- Source
- marketscreener.com
marketscreener.com
Direct company coverage
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000E Growth Benchmark
Neumora Therapeutics, Inc. (NMRA) has been added to the Russell 3000E Growth Benchmark, according to an announcement published on June 29, 2026. This inclusion follows several other additions to various Russell indices on the same day and the prior day, including the Russell 2000
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 30 Jun 2026 03:39
- Source
- marketscreener.com
www.marketscreener.com
Direct company coverage
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Index
Neumora Therapeutics, Inc. (NasdaqGS: NMRA) has been added to the Russell 2000 Index, as well as several other Russell benchmarks including the Russell 2500 Growth, Russell Microcap Growth, Russell 2000 Growth, Russell 3000E Growth, Russell Microcap, Russell 2000 Dynamic, Russell
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 29 Jun 2026 22:10
- Source
- www.marketscreener.com
www.marketscreener.com
Direct company coverage
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000 Index
Neumora Therapeutics, Inc. (NMRA) has been added to the Russell 3000 Index, along with several other Russell indices including the Russell 2000, Russell 2500 Growth, and Russell Microcap Growth benchmarks. This news follows a recent adjustment by Mizuho, lowering Neumora Therapeu
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 29 Jun 2026 17:42
- Source
- www.marketscreener.com
www.marketscreener.com
Direct company coverage
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell Microcap Index
Neumora Therapeutics, Inc. (NasdaqGS: NMRA) has been added to the Russell Microcap Index. The company is a clinical-stage biopharmaceutical firm focused on neuroscience programs and its most advanced candidate, navacaprant, is in Phase 3 trials for depressive disorder. This inclu
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 Jun 2026 16:10
- Source
- www.marketscreener.com
www.marketscreener.com
Direct company coverage
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to Russell 2000 Dynamic Index
Neumora Therapeutics, Inc. (NMRA) has been added to the Russell 2000 Dynamic Index, as well as several other Russell indices including the Russell 2000 Index, Russell 2500 Growth Benchmark, and Russell 3000 Index. This inclusion took place around June 28-29, 2026. The company is
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 29 Jun 2026 16:10
- Source
- www.marketscreener.com
marketscreener.com
Direct company coverage
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to Russell Microcap Growth Benchmark Index
Neumora Therapeutics, Inc. (NasdaqGS:NMRA) has been added to the Russell Microcap Growth Benchmark Index. This news follows several other index additions for the company, including the Russell 2000 Growth and Russell 3000E Growth benchmarks, despite recent development halts and a
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 29 Jun 2026 12:12
- Source
- marketscreener.com
www.marketscreener.com
Direct company coverage
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Growth Benchmark
Neumora Therapeutics, Inc. (NasdaqGS:NMRA) has been added to the Russell 2000 Growth Benchmark. This news follows several recent announcements, including its addition to the Russell Microcap Growth Benchmark, Russell 3000E Growth Benchmark, and Russell Microcap Index. The company
- Tone
- Positive 63/100
- Event
- Market update
- Published
- 29 Jun 2026 11:12
- Source
- www.marketscreener.com
The National Law Review
Direct company coverage
Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of
Levi & Korsinsky has announced an upcoming deadline for a class action lawsuit filed on behalf of investors who suffered losses in Neumora Therapeutics, Inc. (NASDAQ: NMRA) stock. The lawsuit alleges that Neumora Therapeutics made false statements regarding its Phase Three Progra
- Tone
- Negative 28/100
- Event
- Regulatory and legal
- Published
- 28 Jun 2026 17:40
- Source
- The National Law Review
StocksToTrade
Direct company coverage
NMRA Slides As Neumora Kills Navacaprant After Phase 3 Blowup
Neumora Therapeutics Inc. (NMRA) stock slid after the company discontinued its navacaprant program due to failures in Phase 3 trials for major depressive disorder. Analysts have cut price targets significantly, though some maintain Buy or Outperform ratings, citing the company's
- Tone
- Negative 39/100
- Event
- Analyst action
- Published
- 28 Jun 2026 15:37
- Source
- StocksToTrade
Timothy Sykes
Direct company coverage
NMRA Stock Drops As Neumora Axes Failed Depression Drug
Neumora Therapeutics Inc. (NMRA) stock has seen an 8.61% increase despite the failure of its Phase 3 navacaprant trials for major depressive disorder, leading to program discontinuation and significant workforce reduction. Analysts have cut price targets but maintained "Buy" or "
- Tone
- Negative 39/100
- Event
- Market update
- Published
- 28 Jun 2026 14:40
- Source
- Timothy Sykes
TradingView
Direct company coverage
Price to book forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA
This article provides the "Price to book forward" financial metric for Neumora Therapeutics, Inc. (NASDAQ: NMRA). It details that the data is based on human input and sourced from ICE Data Services and FactSet, with SEC filings from Quartr. The core content is a financial data po
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 18:10
- Source
- TradingView
Timothy Sykes
Direct company coverage
NMRA Slides As Neumora Axes Navacaprant After Phase 3 Failure
Neumora Therapeutics Inc. (NMRA) stock slid after the company discontinued its navacaprant program due to Phase 3 trial failures in major depressive disorder. Despite significant price target cuts from analysts at H.C. Wainwright, Needham, and Mizuho, the stock maintains generall
- Tone
- Negative 34/100
- Event
- Analyst action
- Published
- 27 Jun 2026 15:10
- Source
- Timothy Sykes
TradingView
Direct company coverage
Price to sales forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA
This article headline from TradingView focuses on the "Price to sales forward" metric for Neumora Therapeutics, Inc. (NASDAQ: NMRA). The content indicates that the information is part of a financial data section provided by various financial services. The article itself does not
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 07:39
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Neumora Therapeutics, Inc. – BOATS:NMRA
The article references the "Price to sales forward" data for Neumora Therapeutics, Inc. (NMRA) available on TradingView under the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data point without any further analysis or descriptive content, suggesting i
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 21:39
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Neumora Therapeutics, Inc. – BOATS:NMRA
This article provides financial information for Neumora Therapeutics, Inc. (NMRA), specifically focusing on its enterprise value to revenue forward ratio. The content appears to be a stub or a section within a larger financial data platform, indicating the data is "made by humans
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 06:10
- Source
- TradingView
TradingView
Direct company coverage
Neumora Therapeutics, Inc. Actuals & Estimates (NASDAQ:NMRA)
The article provides an overview of Neumora Therapeutics, Inc. (NASDAQ: NMRA) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, volatility, market capitalization, and upcoming earnings report dates. The compan
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 00:50
- Source
- TradingView
Moomoo
Direct company coverage
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $4
Mizuho Securities has reiterated its Buy rating on Neumora Therapeutics (NMRA.US) and maintained a target price of $4. This indicates continued analyst confidence in the company's stock performance.
- Tone
- Positive 77/100
- Event
- Analyst action
- Published
- 23 Jun 2026 12:41
- Source
- Moomoo
Investing.com
Direct company coverage
Neumora stock price target lowered to $4 by Mizuho on trial failure
Mizuho lowered its price target for Neumora Therapeutics (NASDAQ:NMRA) to $4 from $6, while maintaining an Outperform rating, following the failure of its Phase 3 navacaprant trials for depression. The company subsequently announced the discontinuation of the drug and a 35% workf
- Tone
- Negative 25/100
- Event
- Analyst action
- Published
- 22 Jun 2026 11:40
- Source
- Investing.com
Business Wire
Direct company coverage
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
Levi & Korsinsky is investigating Neumora Therapeutics (NMRA) for potential securities fraud after the company's stock collapsed due to the failure of two Phase 3 trials for navacaprant and a subsequent 35% workforce reduction. The investigation focuses on whether previous projec
- Tone
- Negative 9/100
- Event
- Regulatory and legal
- Published
- 18 Jun 2026 14:10
- Source
- Business Wire